JUL 10, 2018 8:45 PM PDT

New Potential Inhibitor Target for Mantle Cell Lymphoma

WRITTEN BY: Mauri Brueggeman

Mantle Cell Lymphoma (MCL) is a rare form of non-Hodgkin’s Lymphoma (NHL) and is so named because of the cells involved.  The mantle is part of follicular zones which surround germinal centers within each lymph node.  The mantle cells become mutagenic and as the mantle cell population grows, the remainder of the lymph cells.  The disease primarily involves the lymph nodes and less often, in about 25% of cases, in the blood or bone marrow.  MCL is usually aggressive.  The morphology of MCL is very similar to Chronic Lymphocytic Leukemia; nuclear irregularities in the cell can be more prominent but are often indistinguishable from CLL cells.  There are molecular techniques that can be used to diagnose MCL including evaluating cell markers like B-cell antigens CD19, CD20 & CD22 and using fluorescence in-site hybridization (FISH) to characterize the present of a translocation between chromosome 11 and chromosome 14.  In 90% of cases of MCL, a protein called cyclin D1 is also present.  Clinicians use these tests and the evaluation of blood levels of lactate dehydrogenase (LDH) and beta-2 microglobulin to determine aggressiveness and guide therapeutic intervention.  The challenge is that while some patients diagnosed with MCL are young and can undergo chemotherapy and a bone marrow transplant, the larger majority have disease identified in their later years at age 68 or older.  There is a need for additional alternative treatments.  

One group of researchers published an article in Oncotarget last month outlining a novel therapeutic option for targeting MCL cells.  The gene product of BMI-1 is required for the growth of MCL cells and is found to be upregulated in MCL.  A selective inhibitor, called PTC596, has been reported to inhibit BMI-1 expression in these cells.  PTC596 initiated apoptosis in MCL cells. 

BMI-1 is a proto-oncogene and polycomb ring finger protein that plays a role in chromatin remodeling and epigenetic labeling processes for regulating embryonic development and self-renewal in stem cells.  It is also protein know to participate in DNA damage repair.  According to the literature published on BMI-1, its divergent expression can also mean resistance to chemotherapy.  The gene is found on chromosome 10 at 10p12.2 and the resultant protein has 326 amino acids. 

The Federal Drug Administration in the US approved acalabrutinib last October for the treatment of adults with MCL but those patients need to have been treated with at least one prior therapy.  This drug was approved using the FDA’s accelerated approval process because there has been such a need for treatment for this very aggressive form of cancer.  Another treatment approach is the use of ibrutinib, which binds to Bruton’s tyrosine kinase (BTK).  This drug has been helpful in the treatment of CLL and can reduce the tumor burden in combination with other therapies.

Sources: Oncotarget, Lymphoma Research Foundation, Therapeutic Advances in Hematology, GeneCardsSuite, FDA,

About the Author
  • Mauri S. Brueggeman is a Medical Laboratory Scientist and Educator with a background in Cytogenetics and a Masters in Education from the University of Minnesota. She has worked in the clinical laboratory, taught at the University of Minnesota, and been in post secondary healthcare education administration. She is passionate about advances and leadership in science, medicine, and education.
You May Also Like
APR 03, 2021
Cancer
New factor plays a key role in immune response
APR 03, 2021
New factor plays a key role in immune response
In a study published recently in Science Immunology, WEHI’s Professor Stephen Nutt, Dr. Michael Chopin, and Mr. Sh ...
APR 13, 2021
Cancer
New efforts to predict which patients will suffer from side effects from immunotherapy
APR 13, 2021
New efforts to predict which patients will suffer from side effects from immunotherapy
The findings from a study published in the Journal for ImmunoTherapy of Cancer give medical professionals a way to predi ...
MAY 16, 2021
Cancer
Can you guess which drug is both antiviral and immunotherapeutic?
MAY 16, 2021
Can you guess which drug is both antiviral and immunotherapeutic?
Hepatitis B virus (HBV) is the most common cause of liver cancer in the world, resulting in approximately 880,000 deaths ...
MAY 26, 2021
Genetics & Genomics
Connecting Bacterial Genes to Human Disease
MAY 26, 2021
Connecting Bacterial Genes to Human Disease
This kind of research gets us closer to using fecal samples to get a snapshot of the microbiome, and make disease risk p ...
MAY 28, 2021
Cancer
Does your birth control increase your risk of breast cancer?
MAY 28, 2021
Does your birth control increase your risk of breast cancer?
A study published recently in EMBO Molecular Medicine considers the biological impacts of progestins from hormonal contr ...
JUN 14, 2021
Cell & Molecular Biology
Can An Omega-3 Fatty Acid Destroy Tumors?
JUN 14, 2021
Can An Omega-3 Fatty Acid Destroy Tumors?
The body needs fatty acts for a variety of functions, and the health benefits of taking fatty acid supplements have long ...
Loading Comments...